Published in Hepatitis Weekly, December 21st, 1998
The vaccine trial is the first human clinical trial to elicit a protective immune response with a DNA vaccine. Interim analysis showed that of the 11 subjects that have completed the vaccination schedule thus far, all seroconverted to antibody levels that are accepted as conferring protection against hepatitis B disease.
The trial enrolled 12 subjects and was designed to test the safety of the vaccine and measure the immune response elicited by...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.